Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

This study has been terminated.
(Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses.)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00317434
First received: April 20, 2006
Last updated: December 10, 2009
Last verified: December 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2007
  Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Publications: